The USFDA has scheduled a Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on Thursday May 18, 2023. The committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), submitted by Pfizer, with a requested indication, in Biologics License Application (BLA-125768) STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.
Back to All Events
Earlier Event: May 12
Cellular, Tissue, and Gene Therapies Advisory Committee
Later Event: May 19
Gastrointestinal Drugs Advisory Committee Meeting